How compounders plan to continue making GLP-1s
Drug compounders and telemedicine companies may be ready to defy a Food and Drug Administration ban on copycat GLP-1 weight-loss drugs that takes effect on Thursday, arguing the law still allows customized versions tailored to patients' needs.
Why it matters: It would be the latest chapter in a battle with brand-name GLP-1 giants Novo Nordisk and Eli Lilly as millions try to get their hands on versions of the blockbuster drugs.
Driving the news: Noom, a digital health company that prescribes compound semaglutide, the active ingredient in some of Novo's GLP-1s, said it will continue to offer compounded versions of the drug beyond the May 22 enforcement deadline.
"The compounding law is clear," said CEO Geoff Cook. "There must be an individual patient benefit to the personalization. And so Noom works with [compounding] pharmacies to provide personalized medication when it's clinically indicated."
When prescribing a compounded GLP-1, Noom has been following a "low and slow" approach to titrating up dosages in patients in a way that is not available in commercial versions of GLP-1s.
Noom said it also prescribes brand name versions of GLP-1 products in a partnership announced earlier this year with Lilly Direct, as well as prescribing non-GLP-1 alternatives.
"I think we are looking to be on very firm ground on when it's clinically indicated," Cook said.
Yes, but: Pharma companies will likely challenge that interpretation.
"Compounders should have already transitioned patients to approved medicine, and anyone continuing to sell mass compounded tirzepatide, including by referring to it as 'personalized,' 'tailored' or something similar, is breaking the law and putting patients at risk," Eli Lilly said in a statement to Axios.
Catch up quick: The FDA allowed compounders to make cheaper copies of the drugs while they were in shortage.
When the agency declared Novo and Lilly's drugs were in sufficient supply earlier this year, compounders were put on notice that most versions of GLP-1s copies would not longer be allowed.
The compounding labs filed a challenge to put tirzepatide, the active ingredient in Lilly's GLP-1s, back in shortage. Earlier this month, a judge ruled against them.
The FDA also allows compounding for prescriptions specific to particular patients.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Lilly partners with Camurus in search of a long-lasting obesity drug
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Looking to defend its giant cardiometabolic health franchise, Eli Lilly is licensing a technology from Swedish biotechnology firm Camurus that promises to produce longer-acting medications. Camurus' FluidCrystal technology is designed to methodically release a therapeutic drug substance into the body over a period of days or months. After an injection, the solution interacts with bodily fluids to transform into a liquid crystalline gel. The gel holds the active ingredient and then slowly degrades, releasing medicine. The deal includes an unspecified upfront payment as part of an initial package that may be worth as much as $290 million, Camurus said Tuesday. That figure also includes payments for reaching certain development and regulatory milestones. Another $580 million could be available for meeting sales goals, along with mid-single digit royalties for successful products. Lilly and rival Novo Nordisk revolutionized diabetes and obesity treatment over the last few years with GLP-1 medicines that opened up one of the biggest markets the pharmaceutical industry has ever seen. In the first quarter alone, Lilly raked in more than $6 billion from sales of tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity. Novo brought in even more from its Ozempic and Wegovy. Now Lilly and Novo are faced with defending the market as a raft of competitors vie to offer newer and better options. Both companies have bulked up their pipelines; Lilly recently claimed success in a Phase 3 trial of a GLP-1 medicine that can be taken in pill form instead of injection. It also has a triple-acting drug in development and a number of other experimental medicines that work differently. The Camurus deal allows Lilly to apply the long-acting technology to as many as four of its drug compounds. That may help the company stave off competitors such as Metsera, which in January announced promising research for its experimental long-acting GLP-1 shot. Meanwhile, Roche recently announced a $1.65 billion deal to expand its obesity pipeline and Amgen and Viking Therapeutics are both moving into late-stage studies of potential rival treatments. Companies are also working on ways to augment the Lilly and Novo medicines. Veru is testing a drug designed to help preserve muscle when taken with Novo's Wegovy. Regeneron and others are conducting similar research. Recommended Reading Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
